Source: Annual Congress 2006 - Lung transplantation: clinical issues



Rating:

Share or cite this content

Citations should be made in the following way:
T. Kohnlein, T. Welte, J. Gottlieb (Hannover, Germany). Substitution therapy in Alpha-1 antitrypsin deficiency after lung transplantation. Eur Respir J 2006; 28: Suppl. 50, 4157

Member's Comments

No comment yet.

Related content which might interest you: The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019 Year: 2019 Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency Source: International Congress 2019 – Insights into physiological diagnostic services Year: 2019 Alpha-1 antitrypsin deficiency – a potentially fatal disease Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017 COPD and alpha-1 antitrypsin deficiency emphysema: characteristics and survival after Lung Transplantation Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 Pulmonary administration of alpha1-antitrypsin for the treatment of Alpha1-antitrypsin deficiency Source: Eur Respir J 2003; 22: Suppl. 45, 385s Year: 2003 Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017 Year: 2017 Endobronchial valve treatment in patients with severe emphysema due to alpha-1 antitrypsin deficiency. Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019 Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020 Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency Source: International Congress 2018 – Latest advances in pulmonary rehabilitation assessment and content Year: 2018 Effects of a-1 antitrypsin augmentation therapy and a-1 antitrypsin deficiency in pneumococcal pneumonia in mice Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Alpha-1 antitrypsin deficiency and pulmonary morbidity in patients with primary immunodeficiency disease: A single center experience Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Patients with Alpha-1 antitrypsin Deficiency due to Null mutations have clinical peculiarities and should require personalized pulmonary management Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency Year: 2019